Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Cardinal Health's Sonia T. Oskouei, PharmD, BCMAS, DPLA.
Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.
Transcript
According to Cardinal Health’s 2022 report, only 40% of ophthalmologists reported being “very familiar” with biosimilars. What needs to be included in educational material aimed at these specialists specifically to increase that statistic?
Ophthalmology market research and our own market research at Cardinal Health has really revealed hesitation when it comes to biosimilars at this stage. In fact, when we looked at trends earlier when the first biosimilar was approved and launched in oncology, believe it or not, there were similar perceptions associated biosimilars amongst oncologists. Now, you see the strong adoption that we have an oncology today.
As we're entering these new therapeutic areas, with ophthalmology being the latest, we are seeing this hesitation and lack of familiarity, where there's a desire for more information and the need for more information to help build clinical confidence in these agents. So, any type of data or evidence in understanding of the FDA approval pathway and the associated scientific rigor from the FDA is key to helping build clinical confidence.
I will say in ophthalmology it's almost trickier because unlike oncology and rheumatology, there is not this robust international experience in ophthalmology with ophthalmology biosimilars. In fact, the US is going to be one of the first countries to have an ophthalmology biosimilar available. So, we are positioned to be a source of generating real-world evidence and data to support future confidence in these agents as more products are anticipated to come in the retina space.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris
Published: June 15th 2024 | Updated: June 14th 2024A poster from the European Hematology Association’s (EHA) 2024 annual meeting in Madrid, Spain, showed similar rates of transfusion avoidance between patients with paroxysmal nocturnal hemoglobinuria who were administered reference eculizumab (Soliris) and those administered an eculizumab biosimilar (SB12).
New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers
June 11th 2024Posters from the American Society of Clinical Oncology annual meeting showcased safety and efficacy data for a trastuzumab biosimilar and an ado-trastuzumab biosimilar in HER2-positive (HER2+) cancers.